Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from ANGLE plc ( (GB:AGL) ).
ANGLE plc announced it will release its interim results for the first half of 2025 on September 9, 2025. Due to planned tube strikes, the analyst meeting will be held virtually, with a live webcast available for analysts. This announcement is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning in the liquid biopsy industry.
The most recent analyst rating on (GB:AGL) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.
Spark’s Take on GB:AGL Stock
According to Spark, TipRanks’ AI Analyst, GB:AGL is a Neutral.
The overall stock score is primarily influenced by financial performance challenges, including negative profitability and cash flows. Technical analysis shows some positive momentum, but valuation concerns due to negative earnings weigh heavily on the score.
To see Spark’s full report on GB:AGL stock, click here.
More about ANGLE plc
ANGLE plc is a leading company in the liquid biopsy industry, offering innovative circulating tumour cell (CTC) diagnostic solutions for research, drug development, and clinical oncology. Their FDA-cleared Parsortix® PC1 System allows for comprehensive downstream analysis of blood samples, including whole cell imaging and molecular analysis. ANGLE focuses on clinical services and diagnostic products, with services provided through GCLP-compliant laboratories and products including the Parsortix system and related consumables.
Average Trading Volume: 806,484
Technical Sentiment Signal: Sell
Current Market Cap: £24.19M
For a thorough assessment of AGL stock, go to TipRanks’ Stock Analysis page.